Search result for biopharmaceutical
INDIAN GOVERNMENT FIRMS PREPARE TO MANUFACTURE COVAXIN
HIGHLIGHTS
- Indian Government firms are preparing to manufacture Covaxin.
- Covaxin was first developed with seed strains received from the National Institute of Virology (NIV).
- Phase 3 clinical trial of Covaxin was co-funded by ICMR. <...
SAMSUNG BIOLOGICS BUILDING NEW PLANT FOR FUTURE GROWTH ENGINES
Highlights –
- Samsung Biologics building new plant for future growth engines.
- The company will produce and manufacture biopharmaceutical products for major pharmaceutical firms.
- The new upcoming plant is said to be worth $1.4 billion.<...
SAMSUNG BIOLOGICS BROADENS HORIZONS WITH INSTALLATION BASE IN SAN FRANCISCO
- Samsung Biologics has opened its first overseas installation in San Francisco as part of the contract policy and manufacturing organization's efforts to provide an unparalleled service network to more than 2,500 life science and biotechnology firms in the city.
- Also at the ...
The U.S. partner SK Biopharma is given an EMA sleepiness node.
SK Biopharmaceuticals is a global pharmaceutical company that develops new medicines to support medical innovation. As part of our quest for the SK Group next-generation rising engine, SK Biopharmaceuticals started to research and the development of new drugs in 1993. The spirited rise of SK Biop...
POP1 Drug Discovery Program Advanced by Propanc Biopharma
Propanc Biopharma, Inc., a biopharmaceutical company creating new cancer therapies for patients with recurrent and metastatic cancer, today reported that the POP1 study and drug discovery program has made great progress in the creation of synthetic variants of both proenzymes, trypsinogen, and ch...
High Times: Now Weed Is the Way to Wellness
At the point when California cast a ballot to authorize recreational cannabis in November 2016, weed smokers could have been pardoned for checking the substance of their bongs. It was a turning point. As the entertainer John Mulaney commented: "This is the first occasion when I've at any...